Peter the Bridge, Saint Petersburg, Russia

News from NEOMED

NEO6860 Phase II Data to be Presented at the American College of Rheumatology’s Annual Meeting

22 November 2017| No Comments
- An analgesic effect demonstrated - - No increase in body temperature nor change in heat pain perception - Montreal, October 30, 2017 - The NEOMED Institute announced today that it will present a poster on the Phase II data for its lead program NEO6860 during the American College of Rheumatology’s A

Read complete news

The NEOMED Institute is Attending the 23rd Annual BioEurope Partnering Conference

|Announcement| No Comments
NEOMED’s 3 key partnering objectives: • Identify licensing partners/financial partners for NEOMED’s therapeutic pipeline • Identify promising in-licensing opportunities • Showcase NEOMED Innovation Center’s expansion project Montreal, October 25th, 2017 - The NEOMED Institute announced today

Read complete news

NEO6860 Clinical Results to be Presented at the Pain & Migraine Therapeutics Summit

20 September 2017|Announcement| No Comments
- NEO6860 is a modality selective TRPV1 antagonist explored for the treatment of OA pain - - A phase II PoC Study is now completed - - NEO6860 is safe and exhibits an analgesic effect - Montreal, September 20, 2017 - The NEOMED Institute announced today that it will present two posters on the clini

Read complete news

PARG Inhibitor Collaboration – BioAuxilium and NEOMED

18 September 2017|Announcement| No Comments
High Throughput Screening Assay for PARG Inhibitors Montreal, September 18th, 2017 - BioAuxilium Research Inc. and the NEOMED Institute announced today the result of a successful collaboration whereby BioAuxilium has developed and validated for NEOMED a custom TR-FRET-based high-throughput screening (HT

Read complete news

© 2017 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia